REG - OptiBiotix Health - Director's dealing <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

01/02/2018 14:25

RNS Number : 6755D
OptiBiotix Health PLC
01 February 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director's dealing
OptiBiotixHealthplc(AIM: OPTI), a lifesciences business developing compoundstotackle obesity, high cholesterol, diabetes was notified today that Neil Davidson, Non-Executive Chairman of the Company, today acquired 165,000 ordinary shares in the Company via his SIPP, representing 0.21% of the Company's issued share capital, at a price of 60 pence per share.
Previously to this notification Mr Davidson did not hold any shares in the Company.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Mark Collingbourne, Chief Financial Officer.
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap Broker
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Neil Davidson
2
Reason for notification
a.
Position/Status
Non-Executive Chairman
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
OptiBiotix Health plc
b.
LEI
213800UKYQFT941QHS14
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code

Ordinary shares
ISIN: GB00BP0RTP38
b.
Nature of the transaction
Purchase of ordinary shares
c.
Price(s) and volume(s)
Price(s) per share
Volume(s)
60 pence
165,000
d.
Aggregated information
- Aggregated Volume
- Price
165,000
60 pence
e.
Date of the transaction
1 February 2018
f.
Place of the transaction
AIM

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHZFLFBVLFLBBB